Condition: Lymphoma Neoplasms · Myeloma Multiple · Severe Infection · Sponsor: Infanta Leonor University Hospital
This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies. Secondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.
This description comes directly from the study's public registry record.
maria stefania infante, MD, pHD · 0034 608008118 · mariastefania.infante@salud.madrid.org
Always discuss trial participation with your own doctor first.
| University Hospital Infanta Leonor | Madrid, Madrid, Spain | Recruiting |
| Infanta Leonor University Hospital | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07609576